IOI Loders Croklaan and Kerry Group have formed a joint venture company to develop and market the nutrition lipid Betapol business. The equal share partnership is centered around Betapol, a specialty lipid for infant nutrition.
The new partnership will be able to reach global markets more effectively, and will stimulate joint developments to extend the Betapol portfolio for infant nutrition, and expand into other key nutrition market segments.
Both partners will bring specific advantages and expertise to the joint venture:
• IOI Loders Croklaan – the creator of Betapol, and first to introduce oleic palmitic oleic-type fats to the market – will continue to manufacture the Betapol product range for the joint venture.
Primary production is at its state of the art enzymatic facility in Pasir Gudang, Malaysia with additional blending capability in Wormerveer, The Netherlands.
The company will continue to manage all product logistics, and will further build upon its commitment to create a traceable and sustainable supply chain.
• Kerry’s €100 million (US$105.6 million) investment in a new Global Technology & Innovation Centre in Ireland will provide a focal point for advancing scientific nutrition research, innovative processing technologies and market leading technology platforms.
Within the partnership, Kerry will co-develop and market Betapol, fulfilling consumer needs and expanding into new markets.
The newly formed joint venture will be responsible for business development and innovation.
Betapol will be integrated into Kerry’s global nutritional ingredients portfolio, backed by global applications, marketing and sales support.
